Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$94.81
-0.5%
$104.58
$13.97
$155.29
$1.39B3.31324,802 shs613,365 shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$28.69
+0.9%
$28.53
$16.24
$45.30
$5.33B0.352.53 million shs2.79 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$99.84
+3.3%
$66.16
$23.30
$104.23
$6.22B2.231.51 million shs4.25 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$59.74
+5.2%
$54.70
$30.00
$63.95
$5.77B0.621.35 million shs8.56 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
+0.22%+2.43%-10.80%+63.23%+539.24%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-3.23%+1.79%-3.73%+69.23%-14.96%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+5.80%+10.38%+48.99%+117.04%+161.29%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+2.16%+7.31%+5.19%+4.22%+78.78%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$94.81
-0.5%
$104.58
$13.97
$155.29
$1.39B3.31324,802 shs613,365 shs
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$28.69
+0.9%
$28.53
$16.24
$45.30
$5.33B0.352.53 million shs2.79 million shs
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$99.84
+3.3%
$66.16
$23.30
$104.23
$6.22B2.231.51 million shs4.25 million shs
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
$59.74
+5.2%
$54.70
$30.00
$63.95
$5.77B0.621.35 million shs8.56 million shs
10 Stocks Set to Soar in 2026 Cover

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
+0.22%+2.43%-10.80%+63.23%+539.24%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-3.23%+1.79%-3.73%+69.23%-14.96%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
+5.80%+10.38%+48.99%+117.04%+161.29%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
+2.16%+7.31%+5.19%+4.22%+78.78%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
2.33
Hold$150.0058.21% Upside
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2.67
Moderate Buy$60.23109.94% Upside
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
2.80
Moderate Buy$74.60-25.28% Downside
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
3.00
Buy$77.2029.23% Upside

Current Analyst Ratings Breakdown

Latest INBX, LEGN, TWST, and XENE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/24/2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
UpgradeSell (E+)Sell (D-)
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Reiterated RatingSell (D-)
6/24/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetOverweight$65.00 ➝ $95.00
6/16/2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
Reiterated RatingSell (D-)
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Set Price Target$89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Boost Price TargetBuy$68.00 ➝ $89.00
6/15/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageBuy$90.00
6/11/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageOverweight$85.00
6/11/2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
Initiated CoverageOverweight$85.00
(Data available from 6/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
$1.30M1,069.89N/AN/A$0.55 per share172.38
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
$1.03B5.18N/AN/A$5.43 per share5.28
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
$409.48M15.18N/AN/A$7.84 per share12.73
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/A$7.53 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$140.05M-$8.39N/AN/AN/AN/A-563.90%-72.32%8/12/2026 (Estimated)
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$296.80M-$0.68N/A15.85N/A-21.98%-24.92%-14.87%8/10/2026 (Estimated)
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$77.67M-$1.33N/AN/AN/A-19.85%-26.73%-19.15%8/3/2026 (Estimated)
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$345.91M-$4.70N/AN/AN/AN/A-49.23%-46.42%8/10/2026 (Estimated)

Latest INBX, LEGN, TWST, and XENE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/14/2026Q1 2026
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
-$1.6750-$2.15-$0.4750-$2.15N/AN/A
5/13/2026Q1 2026
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
-$0.02-$0.03-$0.01-$0.30$306.51 million$305.10 million
5/7/2026Q1 2026
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
-$1.17-$1.17N/A-$1.17$1.36 millionN/A
5/4/2026Q2 2026
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
-$0.49-$0.71-$0.22-$0.71$107.64 million$110.72 million
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
N/AN/AN/AN/AN/A
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/AN/AN/AN/AN/A
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/AN/AN/AN/AN/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
12.58
6.46
6.46
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
N/A
2.13
2.05
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
0.03
2.70
2.42
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
N/A
27.79
27.79

Institutional Ownership

CompanyInstitutional Ownership
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
82.46%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
70.89%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
N/A
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
95.45%

Insider Ownership

CompanyInsider Ownership
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
18.26%
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
0.02%
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
3.08%
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
4.07%
CompanyEmployeesShares OutstandingFree FloatOptionable
Inhibrx Biosciences, Inc. stock logo
INBX
Inhibrx Biosciences
16614.67 million11.99 millionOptionable
Legend Biotech Corporation Sponsored ADR stock logo
LEGN
Legend Biotech
2,965185.74 million185.70 millionOptionable
Twist Bioscience Corporation stock logo
TWST
Twist Bioscience
99062.27 million60.35 millionOptionable
Xenon Pharmaceuticals Inc. stock logo
XENE
Xenon Pharmaceuticals
21096.67 million92.73 millionOptionable

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Inhibrx Biosciences stock logo

Inhibrx Biosciences NASDAQ:INBX

$94.81 -0.50 (-0.52%)
Closing price 04:00 PM Eastern
Extended Trading
$94.73 -0.08 (-0.08%)
As of 04:31 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Inhibrx, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of novel biologic therapeutic candidates. The company's therapeutic candidate includes INBRX-101, an alpha-1 antitrypsin (AAT)-Fc fusion protein therapeutic candidate, which is in Phase 1 clinical trials for use in the treatment of patients with AAT deficiency. It also develops INBRX-109, a tetravalent therapeutic candidate targeting death receptor 5, which is in Phase 2 clinical trials to treat cancers, such as chondrosarcoma, mesothelioma, colorectal cancer, ewing sarcoma, and pancreatic adenocarcinoma; and INBRX-106, a hexavalent agonist of OX40 for a range of oncology indications. The company has license and collaboration agreements with 2seventy bio, Inc. and Bristol-Myers Squibb Company. Inhibrx, Inc. was incorporated in 2009 and is headquartered in La Jolla, California.

Legend Biotech stock logo

Legend Biotech NASDAQ:LEGN

$28.69 +0.26 (+0.91%)
Closing price 04:00 PM Eastern
Extended Trading
$28.75 +0.06 (+0.21%)
As of 04:28 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Legend Biotech Corporation, a clinical-stage biopharmaceutical company, through its subsidiaries, engages in the discovery, development, manufacturing, and commercialization of novel cell therapies for oncology and other indications in the United States, China, and internationally. Its lead product candidate, LCAR- B38M, is a chimeric antigen receptor for the treatment of multiple myeloma (MM). The company also has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It has collaboration and license agreement with Janssen Biotech, Inc. for the development and commercialization of ciltacabtagene autoleucel. The company was founded in 2014 and is based in Somerset, New Jersey. Legend Biotech Corporation is a subsidiary of Genscript Biotech Corporation.

Twist Bioscience stock logo

Twist Bioscience NASDAQ:TWST

$99.84 +3.19 (+3.30%)
Closing price 04:00 PM Eastern
Extended Trading
$100.00 +0.16 (+0.16%)
As of 04:45 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development. It also provides NGS tools comprising library preparation kits, human exome kits, and fixed and custom panels, as well as alliance panels, primarily used within diagnostic tests for various indications, population genetics research and biomarker discovery, translational research, microbiology, and applied markets research; and methylation detection kits for cancer, and rare and inherited disease study, as well as fast hybridization and full RNA sequencing workflow solution. In addition, the company provides synthetic SARS-CoV-2 RNA reference sequences as positive controls for the development of both NGS and reverse transcription-polymerase chain reaction assays; synthetic monkeypox controls; and various respiratory viral controls, including for influenzas, respiratory syncytial virus, rhinoviruses, SARS, MERS, and coronaviruses. Further, it offers SARS-CoV-2 Research Panels, such as the Twist Respiratory Virus Panel and the Pan-Viral Research Panel, for the detection of disease in a research setting; precision DNA libraries used for antibody engineering, affinity maturation, and humanization; and antibody optimization solution to enable simultaneous optimization of multiple characteristics of a given antibody. The company was incorporated in 2013 and is headquartered in South San Francisco, California.

Xenon Pharmaceuticals stock logo

Xenon Pharmaceuticals NASDAQ:XENE

$59.74 +2.96 (+5.21%)
Closing price 04:00 PM Eastern
Extended Trading
$60.14 +0.39 (+0.66%)
As of 04:43 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the development of therapeutics to treat patients with neurological disorders in Canada. Its clinical development pipeline includes XEN1101, a novel and potent Kv7 potassium channel opener, which is in Phase 3 clinical trials for the treatment of epilepsy and other neurological disorders. The company has a license and collaboration agreement with the Neurocrine Biosciences, Inc. for the development of NBI-921352, a selective Nav1.6 sodium channel inhibitor that is in Phase 2 clinical trials for the treatment of SCN8A developmental and epileptic encephalopathy, and other indications, including adult focal epilepsy. Xenon Pharmaceuticals Inc. was incorporated in 1996 and is headquartered in Burnaby, Canada.